SCHEMBL2685665

SCHEMBL2685665

CNc1cc(-c2cc(NC(=O)[C@H](Cc3ccc(F)cc3)NCC#N)n(C)n2)ccn1

nearest known ligand 0.80

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GPR142 Q7Z601 12/20 0.80
MAPT P10636 2/20 0.40
SCN9A Q15858 1/20 0.37
RAB9A P51151 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
RIPK3 Q9Y572 1/20 0.35
NR3C2 P08235 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686575 0.89 GPR142 (1.00) GPR142MAPTSCN9ARAB9APTGDR2
SCHEMBL2686593 0.89 GPR142 (1.00) GPR142MAPTSCN9ARAB9APTGDR2
SCHEMBL2685698 0.86 GPR142 (0.80) GPR142MAPTSCN9A
SCHEMBL2684626 0.85 GPR142 (0.77) GPR142MAPTSCN9ANR3C2
SCHEMBL2686591 0.85 GPR142 (0.75) GPR142MAPTSCN9ARAB9APTGDR2
SCHEMBL2685660 0.85 GPR142 (0.67) GPR142MAPTRAB9APTGDR2RIPK3
SCHEMBL2684060 0.84 GPR142 (0.75) GPR142MAPTSCN9APTGDR2NR3C2
SCHEMBL2685663 0.84 GPR142 (0.80) GPR142MAPTSCN9AMAPK14
SCHEMBL2686843 0.83 GPR142 (0.76) GPR142MAPTSCN9ARAB9APTGDR2
SCHEMBL2686730 0.83 GPR142 (0.76) GPR142MAPTSCN9AMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885MAPT 4112/4885SCN9A 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.